Javelin wins OK to sell pain medication in Scotland

Javelin Pharmaceuticals Inc. of Cambridge said today that it has gotten approval to market its pain medication Dyloject in Scotland.

Javelin won similar approval for Dyloject in the United Kingdom in October.

Dyloject is an injectable form of diclofenac sodium, a widely used anti-inflammatory medicine for postoperative pain that is administered by slow infusion.

According to Javelin, Dyloject is more cost-effective and can be administered more quickly than medication delivered by slow infusion.

The company hopes to win approval for Dyloject in the United States next year.

In morning trading on the American Stock Exchange, shares of Javelin were unchanged at $2.90.
(By Chris Reidy, Globe staff)